Accessibility Menu
 
Jade Biosciences logo

Jade Biosciences

(NASDAQ) JBIO

Current Price$17.86
Market Cap$882.27M
Since IPO (2025)+76%
5 YearN/A
1 Year+90%
1 Month+28%

Jade Biosciences Financials at a Glance

Market Cap

$882.27M

Revenue (TTM)

$0.00

Net Income (TTM)

$127.41M

EPS (TTM)

$-5.45

P/E Ratio

-3.28

Dividend

$0.00

Beta (Volatility)

0.13 (Low)

Price

$17.86

Volume

16,380

Open

$18.18

Previous Close

$17.86

Daily Range

$17.41 - $18.28

52-Week Range

$6.57 - $100.10

JBIO News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jade Biosciences

Industry

Biotechnology

Employees

55

CEO

Tom Frohlich, MBA

Headquarters

Waltham, MA 02453, US

JBIO Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-45%

Return on Capital

-28%

Return on Assets

-36%

Earnings Yield

-30.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$882.27M

Shares Outstanding

49.32M

Volume

16.38K

Short Interest

0.00%

Avg. Volume

400.26K

Financials (TTM)

Gross Profit

$26.00K

Operating Income

$113.54M

EBITDA

$113.54M

Operating Cash Flow

$94.69M

Capital Expenditure

$196.00K

Free Cash Flow

$94.89M

Cash & ST Invst.

$336.16M

Total Debt

$724.00K

Jade Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$9.00K

-12.5%

Gross Margin

0.00%

N/A

Market Cap

$882.27M

N/A

Market Cap/Employee

$17.65M

N/A

Employees

50

N/A

Net Income

$67.58M

-1144.6%

EBITDA

$34.90M

-550.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$335.43M

+328.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$724.00K

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-36.43%

N/A

Return on Invested Capital

-28.07%

N/A

Free Cash Flow

$33.65M

-190.2%

Operating Cash Flow

$33.65M

-190.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TECXTectonic Therapeutic, Inc.
$30.72-1.19%
LYELLyell Immunopharma, Inc.
$22.39-6.12%
CTNMContineum Therapeutics, Inc. Class A Common Stock
$12.87+0.31%
XOMAXOMA Royalty Corp.
$36.74-0.05%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.61+0.02%
CRWVCoreWeave
$102.00+0.11%
NOKNokia
$9.46-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$6.44-0.05%

Questions About JBIO

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.